title: Poly (ethylene)-glycol conjugated solid lipid nanoparticles of noscapine improve biological half-life, brain delivery and efficacy in glioblastoma cells.
abstract: Noscapine crosses blood-brain-barrier and inhibits proliferation of glioblastoma cells. However, short plasma half-life and rapid elimination necessitate the administration of multiple injections for successive chemotherapy. Noscapine bearing solid lipid nanoparticles, Nos-SLN and poly (ethylene)-glycol conjugated solid lipid nanoparticles of noscapine, Nos-PEG-SLN of 61.3 ± 9.3-nm and 80.5 ± 8.9-nm containing 80.4 ± 3.2% and 83.6 ± 1.2% of Nos, were constructed. First order kinetic and Higuchi equation were followed to release the Nos at intracellular pH~4.5. Further, a decrease in IC₅₀ (Nos; 40.5 μM>Nos-SLN; 27.2 μM>20.8 μM) and enhanced subG1 population were observed in U87cells. Plasma half-life was enhanced up to ~11-fold and ~5-fold by Nos-PEG-SLN and Nos-SLN which significantly (P<0.05) deposits 400.7 μg/g and 313.1 μg/g of Nos in comparison to 233.2 μg/g by drug solution. This is first report demonstrating a workable approach to regulate the administration of multiple injections of Nos, warranting further in vivo tumor regression study for superior management of brain cancer.
  
  
  BACKGROUND
  This report describes a possible approach to regulate the administration of multiple injections of Noscapine using solid lipid nanoparticles. The data warrant further in vivo tumor regression studies for optimal management of glioblastoma, a generally very poorly treatable brain cancer.
authors.affiliation: Department of Pharmaceutics, Hindu College of Pharmacy, Sonepat (Haryana) India.
authors.forename: Jitender
authors.initials: J
authors.lastname: Madan
authors.forename: Ravi Shankar
authors.initials: RS
authors.lastname: Pandey
authors.forename: Vikas
authors.initials: V
authors.lastname: Jain
authors.forename: Om Prakash
authors.initials: OP
authors.lastname: Katare
authors.forename: Ramesh
authors.initials: R
authors.lastname: Chandra
authors.forename: Anju
authors.initials: A
authors.lastname: Katyal
mesh_terms: D001921:Brain / Q000378:metabolism*; D001932:Brain Neoplasms / Q000473:pathology*; D045744:Cell Line, Tumor; D005909:Glioblastoma / Q000473:pathology*; D006207:Half-Life; D006801:Humans; D006863:Hydrogen-Ion Concentration; D008055:Lipids; D053758:Nanoparticles; D009665:Noscapine / Q000008:administration & dosage* / Q000737:chemistry / Q000493:pharmacokinetics; D011092:Polyethylene Glycols / Q000737:chemistry*; D033362:Powder Diffraction
chemical_list: D008055:Lipids; D011092:Polyethylene Glycols; D009665:Noscapine